Company intelligence / Profile preview

Evielab

Ownership: Private
Development stage: Commercial

Overview

Evielab has launched solid sublingual micropearls containing CBD and CBG for health and wellness. Consumer studies report high satisfaction rates with improvements in sleep, pain reduction, and relaxation. The product is legal under French regulations as it contains less than 0.2% THC.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (CBD/cannabidiol)Small molecule (CBG/cannabigerol)
Industry: Food & Nutrition

Drug pipeline

1 asset

cannabidiol + cannabigerol

Commercial

Indications: Pain, Sleep disorders, Anxiety, Sports recovery, Sexual dysfunction, Immunity, Focus

Beyond the preview

Go deeper on Evielab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evielab.

Explore the full profile